BVNKF:OTCMKTS
Bavarian Nordic A/S
US$ ३६.०६
०.००%
(०.००) 1D
अक्टोबर ८, १५:४६:२५ GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BVNKF...
Mkt. cap
२.७७ अरब
Avg. vol.
१४.००
Volume
०.००
52-wk high
US$ ३७.२२
52-wk low
US$ २७.६९
Beta
१.४६
Shares outstanding
७.९३ करोड
No. of employees
२ हजार
Mkt. cap
२.७७ अरब
Avg. vol.
१४.००
Volume
०.००
52-wk high
US$ ३७.२२
52-wk low
US$ २७.६९
Beta
१.४६
Shares outstanding
७.९३ करोड
No. of employees
२ हजार
News stories
From web sources and news partners
GlobeNewswire
·
४० मिनेट पहिले
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quiver Quantitative
·
४० मिनेट पहिले
RedCloud Holdings plc Receives Nasdaq Delisting Determination, Appeals Decision and Plans Share Consolidation
Simply Wall Street
·
१३ मिनेट पहिले
Raised Outlook Could Change The Case For NetApp Stock
Seeking Alpha
·
२ घण्टा पहिले
Nasdaq tumbles 2%, and these 10 stocks have fueled the selloff
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S